Scarica l'app Stockscreener
347.94
1.51%
-5.34
Dopo l'orario di chiusura:
347.78
-0.16
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$353.28
Aprire:
$352.72
Volume 24 ore:
1.60M
Relative Volume:
0.58
Capitalizzazione di mercato:
$187.56B
Reddito:
$36.74B
Utile/perdita netta:
$7.71B
Rapporto P/E:
24.45
EPS:
14.2333
Flusso di cassa netto:
$8.10B
1 W Prestazione:
-1.48%
1M Prestazione:
-9.79%
6M Prestazione:
+16.99%
1 anno Prestazione:
+13.82%
Intervallo 1D:
$345.87
$354.16
Intervallo di 1 settimana:
$345.87
$357.00
Portata 52W:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
347.94 | 187.56B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh Trade Ideas — BMFBOVESPA:AMGN34 - TradingView
Amgen Inc. $AMGN Position Boosted by JB Capital LLC - MarketBeat
A Look At Amgen (AMGN) Valuation After New Repatha Data And Zai Lab Oncology Collaboration - simplywall.st
Zai Lab Limited And Amgen Inc. Collaborate To Advance DLL3 Targeted Combination Therapy In Small Cell Lung Cancer - BioPharma APAC
Thurston Springer Miller Herd & Titak Inc. Acquires 3,354 Shares of Amgen Inc. $AMGN - MarketBeat
SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - IndexBox
Amgen Beats Estimates by $400 Million in Q4: Here’s Why Analysts Target $350 - TIKR.com
Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study - TipRanks
Dorato Capital Management Invests $1.58 Million in Amgen Inc. $AMGN - MarketBeat
Aberdeen Group plc Acquires 27,107 Shares of Amgen Inc. $AMGN - MarketBeat
How Tavneos Safety Risks and New Oncology Pact Could Rebalance Amgen’s (AMGN) Risk‑Reward Profile - finance.yahoo.com
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance Australia
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory - The Motley Fool
Amgen's Diversification Continues To Pay Off, RBC Says - Moomoo
Turning Up the Volume on IgG4-RD Awareness and Diagnosis - Amgen
Amgen Terminates Early-Stage AMG 378 Study: What Investors Should Watch Next - tipranks.com
Is Amgen Inc. (AMGN) One of the Best Pharma Stocks to Invest in Now? - finance.yahoo.com
Wells Fargo Maintains Amgen(AMGN.US) With Hold Rating, Maintains Target Price $390 - Moomoo
HF Advisory Group LLC Buys 7,548 Shares of Amgen Inc. $AMGN - MarketBeat
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 - GlobeNewswire
Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate - finance.yahoo.com
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: ReportAmgen (NASDAQ:AM - Benzinga
Zai Lab (09688.HK) Enters Global Collaboration with Amgen (AMGN.US) to Explore Novel ADC and BiTE Combination Therapy - AASTOCKS.com
AMGN Stock Price, Quote & Chart | AMGEN INC (NASDAQ:AMGN) - ChartMill
Will FDA Tavneos Safety Scrutiny and New Lung Cancer Combo Trial Change Amgen's (AMGN) Narrative? - simplywall.st
AMGEN INC (AMGNCL.SN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Amgen Inc. Stock: Biotech Leader's Strategic Pipeline and Oncology Focus Drive Long-Term Investor Va - AD HOC NEWS
Zai Lab gains after Amgen clinical trial deal (ZLAB:NASDAQ) - Seeking Alpha
Here's What You Need to Know about Amgen, Inc's AMG-145 - Yahoo
Amgen (AMGN) and Zai Lab Partner for Lung Cancer Treatment Study - gurufocus.com
Once the center of a $3.7 billion buyout, drug blamed for eight deaths draws FDA alert - The Business Journals
Zai Lab Limited and Amgen Inc Enter Global Clinical Trial Collaboration Agreement - MarketScreener
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $432 - Moomoo
A two-drug small cell lung cancer trial pairs Amgen with Zai Lab - Stock Titan
Highline Wealth Partners LLC Sells 4,004 Shares of Amgen Inc. $AMGN - MarketBeat
Nisa Investment Advisors LLC Has $55.22 Million Stake in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Amgen Inc. $AMGN Shares Bought by Moody Lynn & Lieberson LLC - MarketBeat
Amgen Inc. (AMGN): Billionaire Ken Fisher doubles bullish position - MSN
Amgen Inc. (0R0T.IL) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openpr.com
BTC Capital Management Inc. Sells 4,196 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Average Rating of "Hold" by Analysts - MarketBeat
FDA Says Amgen’s Tavneos Linked to Liver Injuries, Deaths - wsj.com
US FDA warns of liver injury cases tied to Amgen's rare disease drug - Reuters
FDA Warns Of Fatal Liver Risks Linked To Amgen Tavneos UseAmgen (NASDAQ:AMGN) - Benzinga
FDA Flags Serious Liver Risks with Amgen's Tavneos (AMGN) - GuruFocus
FDA issues warning for Amgen's Tavneos following serious liver injury cases - Seeking Alpha
Amgen CEO Bob Bradway's 2025 Letter to Shareholders - Amgen
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amgen Inc Azioni (AMGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
0.42%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):